CDEC made four recommendations: Jentadueto (linagliptin with metformin hydrochloride), Fycompa (perampanel) & Edarbi (azilsartan medoxomil potassium) were all recommended, whereas Edarbyclor (azilsartan medoxomil potassium with chlorthalidone) was not recommended.